RSLS, ReShape Lifesciences, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
On 11/12/2021 Anthony Vendetti from Maxim Group brokerage Reiterated the Buy Rating for RSLS with a price target of $8.00.
That is more that 5X from the current price.
Looking forward to...
- ReShape leader in weight loss market
- FDA approved Lap-Band manufacturing moved to the US
- eliminated debt overhang
- ReShape Marketplace - digital health solution
June 30, 2021: Cash and cash equivalents and restricted cash were $40.2 million.
ReShape Market Cap only 50.061M
Shares Outstanding 17.20M
On 7/1/2021, Ben Haynor from Alliance Global Partners...
On 6/17/2021 Alliance Global Partners brokerage Boosted the Price Target for RSLS ReShape Lifesciences stock from $12.00 to $18.50!
ReShape Lifesciences is America's premier weight-loss solutions company.
The FDA-approved Lap-Band® program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling...
